MSMariya I. Skalinskaya

Mariya I. Skalinskaya

*This is an algorithmically generated author record based on publicly available information.

Mariya I. Skalinskaya has a total of 190 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Safety of 5-aminosalicylic acid therapy in the preconception period and during pregnancy in patients with ulcerative colitis: a multi-center, retrospective, registry-based observational study

    by Irina V. Gubonina, Olga Yu. Barysheva, Bella A. Vykova, Anastasia I. Dolgushina, Maria I. Skalinskaya, Olga V. Khlynova, Ekaterina S. Alekseenko, Aynura A. Gamzaeva, Natalia L. Lozovskaya, Silviya R. Ramazanova, et al.

    Background: 5-Aminosalicylates (5-ASA) are first-line therapy for patients with ulcerative colitis (UC). Although the 2022 ECCO Consensus considers 5-ASA to be low-risk, data on their use during pregnancy remain conflicting. Aim: To investigate the course and outcomes of pregnancy in women with UC, as well as the disease activity during gestation, according to adherence to prescribed 5-ASA therapy. Methods: Data from the registries of seven inflammatory bowel disease centers in Russia were analyzed. The analysis included women with UC (International Classification of Diseases, 10th edition code K51) who received 5-ASA therapy alone and for whom medical records contained information on pregnancy course and outcome. Disease and pregnancy courses were compared between two groups: those adherent and those non adherent to prescribed 5-ASA therapy. Adherence was defined as starting 5-ASA at least 3 months before conception and continuing a stable dose admission throughout pregnancy; non adherence was defined as self-discontinuation of therapy upon becoming pregnant. Results: The study included 73 women with UC (48 aged 30 years, 25 aged 30–40 years). Of these, 58.9% received oral 5-ASA only (41 women mesalamine, 2 sulfasalazine), and 41.1% (n = 30) received combination therapy with rectal 5-ASA. In 8.2% (n = 6) of cases, patients switched from oral to combination therapy during pregnancy. The majority (82.2%, n = 60) continued prescribed 5-ASA therapy throughout pregnancy, while 17.8% (n = 13) discontinued it on their own upon becoming pregnant. The overall rate of UC relapse during pregnancy was 39.7% (29/73). UC recurrence was more frequent in the discontinuation group than in the fully adherent group: 92.3% (12/13) and 28.3% (17/60) respectively (p 0.001). Threatened miscarriage was also higher in the discontinuation group: 38.5% (5/13) and 13.3% (8/60) (p = 0.047) respectively. The composite rate of pregnancy complications (threatened miscarriage, preterm birth, early pregnancy termination) was 76.9% (10/13; 95% confidence interval [CI] 49.7–91.8) in non adherent patients vs. 21.7% (13/60; 95% CI 13.1–33.6) in adherent patients (p 0.001). Newborns in the maintenance 5-ASA therapy group more frequently had normal birth weight and Apgar scores (90.5%, n = 48) compared to those born to mothers who discontinued 5-ASA (42.8%, n = 3) (p = 0.007). No adverse events in women or congenital malformations in newborns were registered during 5-ASA treatment before conception and throughout pregnancy. Conclusion: Adherence to maintenance 5-ASA therapy in women with UC is associated with a more favorable pregnancy course and outcomes compared to discontinuation of therapy upon conception.

  • Increased diversity of Blautia species in patients with ulcerative colitis

    by T. Ya. Vakhitov, S. I. Sitkin, M. I. Skalinskaya, T. S. Egorova, T. S. Sall, D. V. Azarov

    Ulcerative colitis (UC) is characterized by pronounced dysbiosis of the gut microbiota, with previous studies implicating multiple bacterial taxa in disease pathogenesis. This study investigated the species-level diversity of Blautia in 24 UC patients and 15 healthy controls (HC) using 16S rRNA gene sequencing and MALDI-TOF mass spectrometry for species identification. Results demonstrated a marked 10.9-fold increase in Blautia abundance in UC patients (mean 44.6% vs. 5.26% in HC, p=0.0003), with four species - B. obeum, B. luti, B. faecis, and unidentified Blautia sp. (ID 375)-accounting for >80% of the genus. Notably, B. luti showed 100% prevalence in UC patients versus 79.2% in HC (p=0.0086). This Blautia expansion paradoxically correlated with reduced abundance of protective bacteria, including Faecalibacterium duncaniae, Anaerostipes hadrus, and Dorea longicatena, and was associated with increased disease severity. Although Blautia species are known butyrate producers with anti-inflammatory properties, their overabundance in UC represents functional dysbiosis, in which the microbiota attempts metabolic compensation but fails to effectively deliver short-chain fatty acids in the pathologically altered colonic environment. The concurrent depletion of mucus-layer-associated bacteria indicates compromised intestinal barrier integrity. These findings establish Blautia diversity as a potential marker of dysbiosis for UC severity, opening new diagnostic and therapeutic avenues for disease stratification and targeted interventions aimed at restoring eubiotic composition through selective bacterial modulation.


  • Administration of the metabiotic complex based on Bacillus subtilis in treatment regimens for inflammatory bowel diseases: focus on intestinal barrier permeability

    by M. I. Skalinskaya, I. G. Bakulin, E. B. Avalueva, I. V. Lapinsky, L. B. Gaikovaya, A. A. Sinitsa

    The aim of the study. To determine the efficacy and safety of using the metabiotic biologically active food supplement «Bactimunal», including a combination of biologically active metabolites of Bacillus subtilis (B. subtilis) strain SA44 and short-chain fructooligosaccharides (scFOS, polyfructosans), prescribed additionally in treatment regimens for patients with inflammatory bowel diseases (IBD).Materials and methods of the study. 80 patients with IBD were examined, the average age was 41.1±11.14 years, of which 40 (50%) patients with UC, and 40 (50%) with CD, 38 (47.5%) men, 42 (52.5%) women. All patients underwent assessment of clinical symptoms of the disease, venousblood and fecal samples were collected to assess the serum level of trefoil factor (TFF), lipopolysaccharides (LPS), fecal zonulin (FZ) and fecal calprotectin (FC). 40 patients with IBD (20 patients with UC and 20 patients with CD) received basic therapy. 40 patients with IBD (20 patients with UC and 20 patients with CD) received the metabiotic Bactimunal 1 capsule 2 times a day in addition to the basic treatment regimens for 28 days. The observation period for patients in both groups was 28 days, at the end of the observation, the severity of clinical symptoms and intestinal permeability markers (TFF, LPS and FC) were re-evaluated. Statistical data processing was performed using the SPSS (Statistical Package for the Social Sciences) program. Values of p0.05). In IBD patients who received adjuvant therapy with Bactimunal, the average pain scores statistically significantly decreased – from 2.65 points at the beginning of the observation to 0.68 points after 28 days (p=0.025). During dynamic control after 28 days, the frequency of bowel movements decreased in both groups (mean frequency 2.74±0.84 bowel movements/day), statistically significant differences between the groups receiving and not receiving Bactimunal were not revealed (p>0.05). In patients who additionally took Bactimunal, the decrease in the scores of urgencies to defecate in both UC and CD was statistically significantly greater than in patients who did not receive the dietary supplement. In patients with IBD from the group receiving additional therapy with Bactimunal, a statistically significant decrease in the frequency of occurrence and severity of flatulence was noted after 28 days compared to patients in the group not receiving the dietary supplement. In all patients with IBD laboratory markers reflecting the state of the mucosal barrier of the gastrointestinal tract were significantly elevated upon inclusion in the study. In IBD patients additionally receiving Bactimunal in their treatment regimens, a decrease in the average TFF level was registered after 28 days of observation. When assessing the LPS indicators, multidirectional changes were obtained. Normalization of FC concentration occurred in 32 (80%) IBD patients taking Bactimunal, compared with 8 (20%) patients who did not receive Bactimunal as adjuvant therapy (OR=1.5; 95% CI 1.4–3.7; p=0.05) (Table 5). In patients with mild IBD, a decrease in the FC level was observed in 62.5% patients taking Bactimunal, in another group of patients, a decrease in the FC level was noted in 38.5% patients (OR=1.6; 95% CI 1.1–2.49; p=0.03).Conclusions. Metabiotic therapy, prescribed in addition to the basic one, is promising in patients with IBD. The results of the study suggest that in the case of mild IBD additional therapy with Bactimunal can contribute to modulation of the permeability of the intestinal barrier and reduction of the inflammatory process.

  • Characterization of the infiltrate in the lamina propria in inflammatory bowel diseases

    by L.I. Bernardelli, F.A. Indeickin, Saint Petersburg Llc National Center For Clinical Morphological Diagnosis, L.G. Matyusheva, A.M. Emelin, M.I. Skalinskaya, A.S. Nekrasova, R.V. Deev

    Introduction. Violated integrity of the local epithelial barrier is considered to contribute significantly to the occurrence of inflammatory bowel diseases. Its subepithelial part includes the components of the lamina propria consisting of granulocytes, macrophages, and lymphocytes, which are directly involved in damaging, inflaming, and regenerating the intestinal mucosa. The aim of the study was to determine the cellular composition of the infiltrate of the lamina propria of various intestinal parts. Materials and methods. We performed 300 histological and 15 immunohistochemical examinations of biopsies of the ileum, rectum, and ascending and sigmoid colons of patients with Crohn’s disease, ulcerative colitis, and irritable bowel syndrome. The biopsies of patients with inflammatory bowel syndrome were included in the comparison group. We determined CD163+ macrophages, CD3+ lymphocytes, CD20+ lymphocytes, CD138+ plasmocytes, and CD117+ mast cells. Results. When comparing the number of infiltrate cells in the rectal lamina propria in inflammatory bowel diseases, we detected that an acute stage of irritable bowel syndrome is characterized by a greater number of neutrophils, eosinophils, macrophages, T-lymphocytes, plasmocytes, mast cells in ulcerative colitis; macrophages in Crohn’s disease were noted. A comparison between nosologies in the acute stage revealed a greater number of macrophages in Crohn’s disease; mast cells in ulcerative colitis. A comparison of the stages of the disease showed a greater number of macrophages in ulcerative colitis in remission and a Crohn’s disease in the acute stage; neutrophils, T-lymphocytes, mast cells in ulcerative colitis in the acute stage. Conclusion. The cellular composition of the infiltrate of the intestinal mucosa varies and depends on the location, nosology, and the phase of the disease. The following diagnostic criteria for inflammatory bowel diseases can be considered as additional ones: a 2-fold increase in the number of macrophages in the ileum in acute Crohn’s disease and a 4-fold and 16-fold increase in the number of mast cells in the ascending and sigmoid colons, respectively, in ulcerative colitis. Keywords: inflammatory bowel diseases, Crohn’s disease, ulcerative colitis, irritable bowel syndrome, infiltrate


  • The cellular-differential composition of the intestinal epithelium in various phases of inflammatory bowel diseases

    by Liudmila I. Bernardelli, Fedor A. Indeickin, Lilia G. Matyusheva, Alexey M. Emelin, Mariya I. Skalinskaya, Anna S. Nekrasova, Roman V. Deev, Fyodor A. Indeikin, Матюшева Лилия Геннадьевна, Скалинская Мария Игоревна

    BACKGROUND: The steady increase in the number of inflammatory bowel diseases and the absence of reliably significant diagnostic markers require the search for new morphological criteria for differential diagnosis. AIM: This study aimed to determine the cellular-differential composition of the intestinal epithelium in the phases of exacerbation and remission in Crohn’s disease and ulcerative colitis. MATERIALS AND METHODS: Tissue samples of 60 patients with inflammatory bowel diseases (Crohn’s disease, n=30; ulcerative colitis, n=30) and with irritable bowel syndrome (control group, n=15) were studied using histological, immunohistochemical, morphometric and statistical methods. RESULTS: Distinct features of the cellular-differential composition of the epithelium in the mucous membrane of the ileum, ascending colon, sigmoid colon, and rectum were identified across these conditions, with differences observed during exacerbation and remission in inflammatory bowel diseases. The proportion of goblet cells in the epithelial lining varied by intestinal region and disease type and phase. Goblet cell differentiation: 25.0% more goblet cells of the superficial epithelium between the crypts of the ileum in acute Crohn’s disease compared with remission (p=0.0002); 42.9% more goblet cells in the superficial epithelium of the ascending colon compared with irritable bowel syndrome (p=0.0001); 23.0% more goblet cells crypt in the sigmoid colon compared with ulcerative colitis in the acute stage (p=0.0024). There were no significant differences in the differentiation of Paneth cells. There was a threefold increase in endocrinocytes in the sigmoid colon in acute Crohn’s disease compared with irritable bowel syndrome (p=0.0238). Nonepithelial differon cells: fewer interepithelial lymphocytes in Crohn’s disease in remission compared with Crohn’s disease in the acute stage by 2.4 times in the sigmoid colon, 4.0 times in the rectum (p 0,0001); compared with irritable bowel syndrome by 4.8 times in the ileum, 2.7 times in the ascending intestine, 4.0 times in the sigmoid colon (p 0,05); 8.0 times in the rectum compared with ulcerative colitis in remission (p=0,0004). Additionally, the study found proliferative activity of crypt cells (mainly goblet-shaped) increased by 4.2 times in the sigmoid colon in acute Crohn’s disease compared with acute ulcerative colitis (p=0,0016). CONCLUSIONS: Morphometric parameters of the cellular-differential composition of the intestinal epithelium can serve as potential differential diagnostic criteria. Acute Crohn’s disease is characterized by a higher proliferation index in the sigmoid colon compared with acute ulcerative colitis, while Crohn’s disease in remission shows a lower number of interepithelial lymphocytes in the rectum compared with ulcerative colitis in remission.


  • Open Access

    Intrahepatic cholestasis of pregnancy: current clinical and treatment and diagnostic approaches

    by Milena A. Formozova, Olesya N. Velmatova, Ekaterina V. Skazyvaeva, Maria I. Skalinskaya, Igor G. Bakulin, Evgeny S. Mikhalin, Скалинская Мария Игоревна, Михайлин Евгений Сергеевич

    BACKGROUND: The article is devoted to the current problem of intrahepatic cholestasis of pregnancy. This disease complicates the course of pregnancy, worsens the quality of life of patients and is a predictor of obstetric and perinatal complications. AIM: To analyze clinical features, epidemiology, treatment, and diagnosis of patients with verified intrahepatic cholestasis of pregnancy, to study the relationship between the level of bile acids and the severity of skin itching and the development of complications in newborns. MATERIALS AND METHODS: Using a retrospective analysis technique, medical histories of patients with intrahepatic cholestasis of pregnancy were studied. RESULTS: Verified intrahepatic cholestasis of pregnancy was found to be associated with the age over 30 years old, high baseline body mass index (more 25 kg/m2), and with consecutive pregnancy. Most patients (64%) were diagnosed with intrahepatic cholestasis after 36 weeks of pregnancy. Skin itching is the main clinical symptom of intrahepatic cholestasis of pregnancy, which in most cases (46.7%) was pronounced. Meanwhile, the intensity of itching, depended on the level of bile acids (p = 0.00000000001). There is a relationship between the degree of increased levels of bile acids and the appearance of various respiratory disorders in newborns (p = 0.003). CONCLUSIONS: The topic under consideration will be of interest to specialists in the field of obstetrics and gynecology, gastroenterology, hepatology, and therapy. The issue of diagnosis and treatment of intrahepatic cholestasis of pregnancy requires further study.

  • Open Access

    Registry of patients with autoimmune liver diseases in St. Petersburg: clinical and epidemiological data

    by Igor G. Bakulin, Svetlana A. Burlakova, Ekaterina V. Skazyvaeva, Maria I. Skalinskaya, Скалинская Мария Игоревна

    BACKGROUND: The problem of autoimmune liver diseases, which include autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis and their overlap syndromes is an urgent problem of modern medicine. This is associated with an increase in the incidence and prevalence of these nosologies in different regions of the world. Absence of an established etiological factor, prolonged asymptomatic or low-symptomatic course, lack of pathognomonic clinical picture, imperfect diagnostic criteria, insufficient awareness of physicians lead to late diagnosis of autoimmune liver diseases and, accordingly, untimely initiation of treatment, which often reduces its effectiveness, affecting the further prognosis and survival rate for this group of patients. Patients with autoimmune liver diseases require long-term, often lifelong therapy and dispensary observation. Epidemiological registries along with autoimmune liver diseases registries, including various nosologies of autoimmune liver diseases, form an important database on the incidence, clinical features, development and course of the disease, variants of therapy and response to therapy, presence of extrahepatic manifestations as well as allow analysis of all data in dynamics. AIM: To analize data on various nosologies of autoimmune liver diseases, demographics, clinical symptoms, timing of the first symptoms, timing of diagnosis, and the nature of extrahepatic manifestations. MATERIALS AND METHODS: This article presents data from the autoimmune liver diseases Register of the North-West Hepatology Centre (North-West Autoimmune Liver Diseases Register) of the North-Western State Medical University named after I.I. Mechnikov. RESULTS: The study obtained data on the nosological structure, demographic characteristics, timing of diagnosis verification, clinical symptoms and extrahepatic manifestations of autoimmune liver diseases. CONCLUSIONS: Establishing registers of autoimmune liver diseases, providing information about patients with these diseases, will help to assess the effectiveness of examination and treatment methods, factors affecting the course and prognosis of the disease. Analysis of the data obtained will help to develop screening programs, diagnostic algorithms and differential diagnostics of autoimmune liver diseases, which, in turn, will facilitate the diagnostic process, shorten the time of diagnosis, make it possible to start therapy earlier and, consequently, improve the prognosis and survival rate for this group of patients.


  • Open Access

    Inflammatory bowel diseases: Transformation of representations. A review

    by I V Maev, I G Bakulin, M I Skalinskaya, E V Skazyvaeva

    The global burden of inflammatory bowel disease (IBD) is currently significant and continues to grow due to the increasing prevalence of ulcerative colitis (UC) and Crohn's disease (CD), the increasing costs of diagnosis and treatment, and the high level of disability in patients with this disease. Categories, which leads to the search for risk factors and predictors of aggressive course and extraintestinal manifestations. According to the latest data, the prevalence of UC in Russia is 16.6 per 100 000 population, the annual registered increase is 11.3%; the prevalence of CD is 5.6 per 100 000 population, and the increase is 13.7%. In the Russian population of patients with IBD, the average age of disease onset is 35.3 years for UC and 31.2 years for CD. Moreover, in 89.3% of patients with UC, it took at least 2 years to verify the diagnosis, and in CD, within 2 years from the onset of clinical symptoms, the diagnosis was established in only 72.6% of patients. One of the dominant characteristics of IBD is its multisystem nature, which leads to the development of extraintestinal manifestations (ECM), which can be observed in 50–60% of patients, while up to 25% of patients with IBD have several EMC and the most common variants are joint lesions. A higher frequency of extraintestinal manifestations is observed in CD (up to 45% of patients), in female patients, in smokers and with a longer duration of the disease. To predict clinical remission, the level of fecal calprotectin and CRP, the need for glucocorticosteroids are important, to predict endoscopic remission – the level of fecal calprotectin, and to predict histological remission, an endoscopic Schroeder index value of ≤1 is important. The absolute risk of developing colorectal cancer in IBD remains relatively low, ranging from 1.1 to 5.4% after 20 years of disease. The main risk factors for IBD are total intestinal damage, high inflammatory activity, the stricturing phenotype of CD and the presence of primary sclerosing cholangitis.


  • Open Access

    Consensus on controversial issues of the surgery for Crohn’s disease by Delphi method

    by Yu. A. Shelygin, S. I. Achkasov, I. V. Reshetov, I. V. Mayev, O. M. Drapkina, E. A. Belousova, A. V. Vardanyan, B. A. Nanaeva, D. I. Abdulganieva, L. V. Adamyan, et al.

    AIM: to establish the consensus on controversial issues of the surgery for Сrohn’s disease by Delphi method.METHODS: a cross-sectional study was conducted by the Delphi method. 62 experts voted intramural and anonymous (31.03.23). 5 statements from the current edition of clinical guidelines were selected for correction by working group and further voting [2]. Based on the practical experience of the working group and literature data, 3 new statements were created also. Statements that do not reach the required level of agreement (80% or more) will be subjected to Round 2 of the Delphi method.RESULTS: all experts took part in the anonymous voting. The panel of experts is represented by 8 different areas of practical medicine and the median of the professional experience of the respondents was 30 (12–49) years. Of the 8 statements submitted for voting, consensus (80% or more) was reached on 6 out of 8. 2 statements have been revised by working group for the distance 2nd round of the Delphi study. Consensus (more than 80%) was reached on both.CONCLUSION: a cross-sectional study by the Delphi method provided the opinions of a panel of experts on controversial issues in the surgical treatment of Crohn’s disease. Statements that reach consensus will be included by the working group in a new edition of clinical guidelines of Crohn’s disease.


  • Open Access

    Clostridioides difficile infection: diagnosis, treatment, and prevention Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine, the Gastroenterological Scientific Society of Russia, and the North- West Society of Gastroenterologists and Hepatologists

    by O. M. Drapkina, L. B. Lazebnik, I. G. Bakulin, M. S. Zhuravleva, N. V. Bakulina, E. V. Skazyvaeva, S. I. Sitkin, M. I. Skalinskaya, O. I. Solovyeva, E. Yu. Eremina, et al.

    Clostridioides difficile infection (CDI) is the most common cause of antibiotic-associated diarrhea, and an important cause of nosocomial infection. Since the publication of the National Guidelines (2016, 2017), new data have been accumulated on the genetic structure and pathogenic properties of the most common causative agent of severe forms of antibiotic- associated diarrhea, which has led to the reclassifi cation of the pathogen, formerly known as Clostridium diffi cile, to Clostridioides difficile. Laboratory algorithms have been developed to diagnose CDI and determine the toxigenicity of strains reliably. New data on the effectiveness of antibacterials have been published, monoclonal antibodies to toxin B (bezlotoxumab) have been introduced into clinical practice to prevent CDI recurrence, and fecal microbiota transplantation has been proposed. Over the past 5 years, many international guidelines on the management of adult patients with CDI have also been updated (USA, EU). In the last decade, including due to the COVID-19 pandemic, there has been an increase in CDI incidence. Considering therelevance of CDI, new data on the pathogen, and domestic features, the Russian Scientific Medical Society of Internal Medicine, the Gastroenterological Scientific Society of Russia, and the North-West Society of Gastroenterologists and Hepatologists developed these clinical guidelines.